Review: Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: How similar and distinct?

Arthritis and Rheumatology

Volumn 66, Issue 8, 2014, Pages 1967-1978

  Herzog, Erica L ^a   Mathur, Aditi ^a   Tager, Andrew M ^b   Feghali Bostwick, Carol ^c   Schneider, Frank ^d   Varga, John ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMATINIB; MUCIN 5B; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NINTEDANIB; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; RITUXIMAB; STEROID;

ARTERY INTIMA PROLIFERATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRONCHIECTASIS; CELL DAMAGE; CELL INFILTRATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIGITAL CLUBBING; DISEASE ASSOCIATION; DYSPNEA; ENVIRONMENTAL EXPOSURE; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; GENETIC ASSOCIATION; GENETIC CODE; HERITABILITY; IMMUNE DYSREGULATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG FUNCTION; LUNG VOLUME; MACROPHAGE ACTIVATION; NONHUMAN; ORGANIZING PNEUMONIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT ASPIRATION; RESPIRATORY FUNCTION; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TELANGIECTASIA; TISSUE INJURY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84905040885     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38702     Document Type: Review

References (78)

1. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al, on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
4. Manno RL, Wigley FM, Gelber AC, Hummers LK,. Late-age onset systemic sclerosis. J Rheumatol 2011; 38: 1317-25.
5. Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G,. Scleroderma lung disease. Eur Respir Rev 2013; 22: 6-19.
6. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the Scleroderma Lung Study. Chest 2009; 136: 1333-40.
7. Murray LA, Rubinowitz A, Herzog EL,. Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease? Curr Opin Rheumatol 2012; 24: 656-62.
8. Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NS, Nicholson AG, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232: 560-7.
9. Lynch DA,. High-resolution CT of idiopathic interstitial pneumonias. Radiol Clin North Am 2001; 39: 1153-70.
10. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-6.
11. Corte TJ, Wort SJ, Wells AU,. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 7-19.
12. Altman RD, Medsger TA Jr, Bloch DA, Michel BA,. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
13. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007; 132: 214-20.
14. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625-35.
15. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-91.
16. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390-4.
17. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-77.
18. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-9.
19. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187: 768-75.
20. Asano Y, Sato S,. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep 2013; 15: 382.
21. Peng X, Mathai SK, Murray LA, Russell T, Reilkoff R, Chen Q, et al. Local apoptosis promotes collagen production by monocyte-derived cells in transforming growth factor β1-induced lung fibrosis. Fibrogenesis Tissue Repair 2011; 4: 12.
22. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, et al. Future directions in idiopathic pulmonary fibrosis research: an NHLBI workshop report. Am J Respir Crit Care Med 2014; 189: 214-22.
23. Fang F, Ooka K, Bhattacharyya S, Wei J, Wu M, Du P, et al. The early growth response gene Egr2 (alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol 2011; 178: 2077-90.
24. Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci U S A 2011; 108: 10562-7.
25. Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS One 2009; 4: e5981.
26. + regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1121-30.
27. Pochetuhen K, Luzina IG, Lockatell V, Choi J, Todd NW, Atamas SP,. Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol 2007; 171: 428-37.
28. Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C,. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011; 13: R166.
29. Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol 2013; 191: 2089-95.
30. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-34.
31. Kondoh Y, Taniguchi H, Yokoi T, Nishiyama O, Ohishi T, Kato T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005; 25: 528-33.
32. Elhaj M, Charles J, Pedroza C, Liu X, Zhou X, Estrada-Y-Martin RM, et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 2013; 40: 1114-20.
33. Christmann RB, Mathes A, Affandi AJ, Padilla C, Nazari B, Bujor AM, et al. Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor β. Arthritis Rheum 2013; 65: 1335-46.
34. Atamas SP, White B,. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003; 14: 537-50.
35. He C, Ryan AJ, Murthy S, Carter AB,. Accelerated development of pulmonary fibrosis via Cu,Zn-superoxide dismutase-induced alternative activation of macrophages. J Biol Chem 2013; 288: 20745-57.
36. Moore MW, Herzog EL,. Regulation and relevance of myofibroblast responses in idiopathic pulmonary fibrosis. Curr Pathobiol Rep 2013; 1: 199-208.
37. Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, et al. Reversal of persistent fibrosis in aging by targeting nox4-nrf2 redox imbalance. Sci Transl Med 2014; 6: 231ra47.
38. Booth AJ, Hadley R, Cornett AM, Dreffs AA, Matthes SA, Tsui JL, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 2012; 186: 866-76.
39. Brissett M, Veraldi KL, Pilewski JM, Medsger TA Jr, Feghali-Bostwick CA,. Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum 2012; 64: 272-80.
40. Lindahl GE, Stock CJ, Shi-Wen X, Leoni P, Sestini P, Howat SL, et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res 2013; 14: 80.
41. Renzoni EA, Abraham DJ, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G, et al. Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts. Respir Res 2004; 5: 24.
42. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PloS One 2007; 2: e482.
43. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA,. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63: 783-94.
44. Gardet A, Zheng TS, Viney JL,. Genetic architecture of human fibrotic diseases: disease risk and disease progression. Front Pharmacol 2013; 4: 159.
45. Feghali-Bostwick C, Medsger TA Jr, Wright TM,. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956-63.
46. Assassi S, Radstake TR, Mayes MD, Martin J,. Genetics of scleroderma: implications for personalized medicine? BMC Med 2013; 11: 9.
47. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309-17.
48. O'Dwyer DN, Armstrong ME, Trujillo G, Cooke G, Keane MP, Fallon PG, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188: 1442-50.
49. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-9.
50. Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012; 142: 1584-8.
51. Zhu H, Luo H, Li Y, Zhou Y, Jiang Y, Chai J, et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression. J Clin Immunol 2013; 33: 1100-9.
52. Schachna L, Medsger TA Jr, Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54: 3954-61.
53. Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, et al, for the Scleroderma Lung Study Research Group. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63: 2797-808.
54. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ,. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-77.
55. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laque R, Vilardell-Tarres M,. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011; 30: 1393-8.
56. Tzouvelekis A, Bouros E, Oikonomou A, Ntolios P, Zacharis G, Kolios G, et al. Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. Pulm Med 2011; 2011: 849035.
57. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49: 271-80.
58. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506.
59. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al, for the ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92.
60. Richeldi L, du Bois, RM, Raghu G, Azuma A, Brown KK, Costabel U, et al, for the INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82.
61. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70: 1003-9.
62. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102: 150-5.
63. Gerbino AJ, Goss CH, Molitor JA,. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008; 133: 455-60.
64. Fischer A, Brown KK, Du Bois, RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640-6.
65. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
66. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
67. Nadashkevich O, Davis P, Fritzler M, Kovalenko W,. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-12.
68. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540-6.
69. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30: 517-22.
70. Burt RK, Shah SJ, Gheorghiade M, Ruderman E, Schroeder J,. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: "it is a matter of the heart." J Rheumatol 2012; 39: 206-9.
71. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.
72. Idiopathic Pulmonary, Fibrosis Clinical, Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW,. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-8.
73. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-55.
74. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-42.
75. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-9.
76. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al, for the INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-8.
77. Noth I, Olman M, for the IPFnet. Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? A reply to Tzouvelekis [letter]. Am J Respir Crit Care Med 2013; 187: 214.
78. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-87.